AN2 Therapeutics, Inc. (ANTX)Healthcare | Biotechnology | Menlo Park, United States | NasdaqGS
4.30 USD
-0.10
(-2.273%) ⇩
(Oct. 12, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 6:24 a.m. EDT
The investment case for AN2 Therapeutics is currently broken by a catastrophic multi-year decline. Despite a recent price rebound and a positive year-over-year gain in the most recent fiscal year, the stock has erased over 93% of its value since 2022. This deep structural deterioration, combined with negative earnings, negative free cash flow, and a massive cash burn rate, renders the business a high-risk speculative vehicle rather than a viable long-term holding. The recent rally appears to be a technical bounce off lows rather than a fundamental turnaround, especially given the company's precarious financial position and shareholder investigations. With no dividend to provide income and a balance sheet that requires constant capital raising, the long-term outlook remains severely impaired. Short-term momentum is mixed; while the price has stabilized recently, the overwhelming options flow suggests traders are still betting against further downside, making any near-term entry a gamble against the trend. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.097196 |
| MSTL | 0.100882 |
| AutoETS | 0.113425 |
| AutoARIMA | 0.119777 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 37% |
| H-stat | 0.45 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.165 |
| Excess Kurtosis | -0.76 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Market Cap | 162,265,824 |
| Forward P/E | -5.38 |
| Beta | -0.98 |
| Website | https://www.an2therapeutics.com |
As of Oct. 10, 2026, 6:24 a.m. EDT: Speculators are positioning for a continued downtrend, evidenced by significant open interest in out-of-the-money puts expiring in April 2027 at the $4.0 strike. Conversely, call activity is negligible, with the only notable positioning being a large block of out-of-the-money calls at the $7.0 strike for January 2027, suggesting a speculative 'lottery ticket' bet on a massive recovery rather than a structured bullish thesis. Implied volatility is extremely low across the board, indicating a lack of fear regarding immediate moves but also a lack of capital flowing into the asset.
| Attribute | Value |
|---|---|
| 52 Week Change | 2.4126985 |
| Address1 | 1,300 El Camino Real |
| Address2 | Suite 100 |
| All Time High | 23.58 |
| All Time Low | 0.87 |
| Ask | 5.52 |
| Ask Size | 2 |
| Audit Risk | 10 |
| Average Daily Volume10 Day | 349,020 |
| Average Daily Volume3 Month | 238,803 |
| Average Volume | 238,803 |
| Average Volume10Days | 349,020 |
| Beta | -0.977 |
| Bid | 3.32 |
| Bid Size | 2 |
| Board Risk | 8 |
| Book Value | 2.091 |
| City | Menlo Park |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 10 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 4.3 |
| Current Ratio | 14.322 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 4.41 |
| Day Low | 4.24 |
| Display Name | AN2 Therapeutics |
| Dividend Yield | 0.0 |
| Earnings Timestamp End | 1,755,201,600 |
| Earnings Timestamp Start | 1,755,201,600 |
| Ebitda Margins | 0.0 |
| Enterprise Value | 83,878,816 |
| Eps Current Year | -0.895 |
| Eps Forward | -0.8 |
| Eps Trailing Twelve Months | -1.07 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 5.4918 |
| Fifty Day Average Change | -1.1917996 |
| Fifty Day Average Change Percent | -0.2170144 |
| Fifty Two Week Change Percent | 241.26985 |
| Fifty Two Week High | 7.19 |
| Fifty Two Week High Change | -2.8899999 |
| Fifty Two Week High Change Percent | -0.40194714 |
| Fifty Two Week Low | 1.0 |
| Fifty Two Week Low Change | 3.3000002 |
| Fifty Two Week Low Change Percent | 3.3000002 |
| Fifty Two Week Range | 1.0 - 7.19 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,648,215,000,000 |
| Float Shares | 22,292,682 |
| Forward Eps | -0.8 |
| Forward P E | -5.375 |
| Free Cashflow | -18,017,876 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 21 |
| Fullday Change | -0.099999905 |
| Fullday Change Percent | -2.272725 |
| Fullday Price | 4.3 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.1598 |
| Held Percent Institutions | 0.76884 |
| Implied Shares Outstanding | 37,736,237 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | AN2 Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics. The company's initial candidate includes epetraborole, which is phase 3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease, as well as studying for the treatment of acute melioidosis. It also develops AN2-502998 (AN15368), an investigational, boron-based small molecule in development for the treatment of chronic Chagas disease that is in preclinical trials; and has various research programs targeting the development of novel compounds in oncology and infectious disease based on its boron chemistry platform. It has a license agreement with Anacor Pharmaceuticals, Inc. to use, develop, manufacture, commercialize compounds and products, including epetraborole for the treatment, diagnosis, or prevention of various human diseases; and Brii Biosciences Limited to research, develop, manufacture, and commercialize compounds and products comprising epetraborole in China, Hong Kong, Taiwan, and Macau for the diagnosis, treatment, and prevention of human diseases; and GSK plc for the development of new therapies for TB. AN2 Therapeutics, Inc. was incorporated in 2017 and is headquartered in Menlo Park, California. |
| Long Name | AN2 Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 162,265,824 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_645116379 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -36,276,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 184,907,561 |
| Number Of Analyst Opinions | 2 |
| Open | 4.41 |
| Operating Cashflow | -30,682,000 |
| Operating Margins | 0.0 |
| Overall Risk | 10 |
| Phone | 650 331 9090 |
| Previous Close | 4.4 |
| Price Eps Current Year | -4.8044696 |
| Price Hint | 4 |
| Price To Book | 2.0564322 |
| Profit Margins | 0.0 |
| Quick Ratio | 14.089 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.0999999 |
| Regular Market Change Percent | -2.27273 |
| Regular Market Day High | 4.41 |
| Regular Market Day Low | 4.24 |
| Regular Market Day Range | 4.24 - 4.41 |
| Regular Market Open | 4.41 |
| Regular Market Previous Close | 4.4 |
| Regular Market Price | 4.3 |
| Regular Market Time | 1,791,835,201 |
| Regular Market Volume | 298,465 |
| Return On Assets | -0.30802 |
| Return On Equity | -0.50118 |
| Sand P52 Week Change | 0.17318833 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 37,736,237 |
| Shares Percent Shares Out | 0.066 |
| Shares Short | 2,491,971 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 2,507,571 |
| Short Name | AN2 Therapeutics, Inc. |
| Short Percent Of Float | 0.0784 |
| Short Ratio | 10.71 |
| Source Interval | 15 |
| State | CA |
| Symbol | ANTX |
| Target High Price | 9.0 |
| Target Low Price | 9.0 |
| Target Mean Price | 9.0 |
| Target Median Price | 9.0 |
| Total Cash | 78,387,000 |
| Total Cash Per Share | 2.077 |
| Total Debt | 0 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.07 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 3.886475 |
| Two Hundred Day Average Change | 0.4135251 |
| Two Hundred Day Average Change Percent | 0.10640107 |
| Type Disp | Equity |
| Volume | 298,465 |
| Website | https://www.an2therapeutics.com |
| Zip | 94,025 |